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Introduction
The first guidelines (previously called consensus) for 
neonatal parenteral nutrition (PN) prescription were 
published in 2004.1 In 2008, these guidelines were 
updated2 according to the most recent disclosed 
international guidelines issued by recognized scientific 
societies.3,4 Eleven years later, relevant advances in 
clinical practice grounded in research were achieved to 
support the decision-making processes in neonatal PN, 
including the use of ready-to-use PN mixtures provided 
by pharmaceutical companies.
It should be highlighted that the 2008 update2 of neonatal 
PN guidelines resulted in a remarkable adherence by 
neonatologists and the consequent improvement of 
clinical practice5 by Portuguese neonatologists. A survey 
of prescribing practices, answered by 72% of coordinators 
of Portuguese neonatal units, revealed that 83% of the 
units followed the national recommendations,2 87% 
initiated amino acids on the first postnatal day and 
95% started lipids in the first three postnatal days.5 
This performance was superior to what was reported 
in a contemporary systematic review that included four 
European and two American surveys, in which only 
24%-54% of the units started amino acids on the first 
postnatal day and 46%-94% initiated lipids in the first 
three postnatal days.6 Probably due to the absence 
of a recommendation for the preparation of neonatal 
PN performed by pharmacists, some limitations (e.g., 
quality control) were detected in another national 
survey of professionals responsible for neonatal PN 
preparation in Portugal.7 
Very recently, updated guidelines for neonatal, pediatric, 
and adolescent PN, resulting from a joint authorship of 
the European Society of Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN), the European 
Society for Parenteral and Enteral Nutrition (ESPEN), 
the European Society of Pediatric Research (ESPR), and 
the Chinese Society of Parenteral and Enteral Nutrition 
(CSPEN), were published.8 
This update of guidelines for neonatal PN prescription is 
divided into two parts: 
- Part I, herein included, in which the general aspects, 
such as indications and contraindications, formulation 
of admixtures, estimation of osmolality, routes of 
administration, heparinization of central venous 
catheters, storage conditions of solutions and emulsions, 
complications, and clinical and laboratory monitoring 
are reviewed. Recommendations for the prescription of 
fluids, energy, and macronutrients are also reviewed, 
particularly in very and extremely preterm infants. 
- Part II, included in the same issue of the Portuguese 
Journal of Pediatrics, reviews recommendations for 
the prescription of micronutrients, using either an 
individualized prescription with hospital pharmacy 
compounding or commercial ready-to-use solutions, and 
PN recommendations in particular clinical conditions.
Levels of evidence (LoE) and recommendation grades 
(RG) used in the updated guidelines of ESPGHAN/
ESPEN/ESPR/CSPEM are adopted in this document and 
shown in Appendix 1.8
Appendix 2 provides a table for the rapid consulting of 
complete PN prescription in preterm infants.
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APPENDIX 1 - Levels of evidence and recommendation grades8
Levels of evidence (LoE)
LoE Type of evidence
1++ High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++
High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is causal.
2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3 Non-analytic studies, e.g. case reports, case series
4 Expert opinion
RCT - randomized control trial.
Recommendation grades (RG) according to the level of evidence
RG Level of evidence
A
At least one meta-analyses, systematic reviews or RCT rated as 1++, and directly applicable to the target population; or 
A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall 
consistency of results
B
A body of evidence including studies rated as 2++, directly applicable to the target population; or
A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of 
results; or Extrapolated evidence from studies rated as 1++ or 1+
0 Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2++ or 2+
GPP Good practice points: Recommended best practice based on the clinical experience of the guideline development group
APPENDIX 2 - Rapid consulting – Daily doses for preterm infants
First postnatal day Daily increase Maximum
 Fluids (mL/kg/d) 60-100humidity 80%-90% 10-15 160-180
 Energy (kcal/kg/day) 45-55 - 90-120
 Glucose (mg/kg/min) 4-8 qs for glycemia45-120 mg/dL
12
 Amino acids (g/kg/day) > 1.5 0.5-1 3.5
 Lipids (g/kg/day) 1-2         0.5-1 4
 Sodium (mEq/kg/day)
0-2 
Initiate preferably after > 6% 
birthweight lost
-  3-5(up to 7)
 Chloride (mEq/kg/day) Similar to sodium -  Similar to sodium
 Potassium (mEq/kg/day)
1-3
Initiate after urine output > 1 
mL/kg/h
- 1-3
 Calcium (mg/kg/day) 32-80 - 100-140(alternative 88-90)
 Phosphorus (mg/kg/day) Divide calcium dose by 1.3 Divide calcium dose by 1.3 Divide calcium dose by 1.3
 Magnesium (mEq/kg/day) 0.2-0.4 - 0.4-0.6
 Water soluble vitamins (mL/kg/day)
 (Soluvit N Infant ®) 1 -
1
 Lipid soluble vitamins (mL/kg/day)
 (Vitalipid N Infant®) 1-2 1 4
Trace elements
   < 2 weeks of exclusive PN Zinc 400-500 µg/kg/day - Zinc 400-500 µg/kg/day
      > 2 weeks of exclusive PN - -
 Peditrace® 1 mL/kg/day
+ Zinc (to make up 400-500 µg/
kg/day)
PN - parenteral nutrition; qs - quantum satis.
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1. Indications
Parenteral nutrition is indicated when it is not possible 
to establish sufficient enteral nutrition for a prolonged 
period, in particular in the following conditions9,10:
- Prematurity, particularly < 33 weeks gestation;
- Major anomalies of the gastrointestinal tract or those 
affecting its functioning, e.g., esophageal atresia, 
intestinal atresia, gastroschisis, and diaphragmatic 
hernia;
- Conditions severely affecting the digestive tract, e.g. 
necrotizing enterocolitis and short bowel syndrome;
- Newborn infants of < 33 weeks gestation with intrauterine 
growth restriction and abnormalities in the umbilical flow 
by Doppler imaging;
- Severe perinatal asphyxia;
- Congenital cardiac malformations with compromised 
visceral perfusion and during the early period after 
cardiac surgery.
2. Contraindications and limitations
Parenteral nutrition should be used with caution or not 
at all in the following conditions11:
- Dehydration;
- Sustained metabolic acidosis;
- Persistent hydro-electrolytic and metabolic imbalances, 
e.g. metabolic acidosis and marked imbalances in serum 
glucose, sodium, potassium, and calcium;
- Acute renal failure;
- Acute liver failure.
The trace elements provided by PN should be reduced 
or suspended in renal failure, hepatic failure, and 
cholestasis (Part II, section 3.2).
In most situations associated with stress (e.g. surgery, 
sepsis), PN should not be suspended. Instead, individual 
adjustments should be made.12,13
3. Formulation of  admixtures
Generally, binary PN mixtures are used, consisting of two 
separate admixtures, that is, a hydro-electrolytic solution, 
containing glucose, amino acids, electrolytes, and trace 
elements, and a lipid emulsion with added vitamins.14,15
For economic and convenience reasons, an all-in-one 
admixture in a single bag prepared in the hospital 
pharmacy (also called a ternary or three-in-one mixture) 
may be used. This strategy may be conditioned by 
potential changes in physical and chemical compatibility 
and in the stability of several components, leading to non-
detectable precipitation that may cause microemboli, 
and increasing the size of lipid particles.14,15 
4. Compounding and ready-to-use 
solutions
A survey conducted in Portugal in 2009,5 before the 
availability of commercial ready-to-use neonatal PN 
solutions, revealed that PN compounding (individualized 
preparation in hospital pharmacy) was used in all 
neonatal units. In the vast majority of these units, 
computer assisted prescription was used, a procedure 
that is known to improve prescription efficiency and 
reduce prescribing errors, saving neonatologists and 
pharmacists time with calculations and validations.16 
The PN compounding should be centralized in hospital 
pharmacy, following a safe method to ensure aseptic 
conditions, reduce preparation errors, validate compatibility 
and stability, and adjust the prescribed intakes.17
Several Portuguese units use the PN mixtures of fixed 
composition prepared in hospital pharmacy, containing 
glucose, calcium, and amino acids in order to provide 
amino acids during weekends when PN compounding is 
unavailable.5
Recently, ready-to-use neonatal PN solutions with fixed 
composition and guaranteed stability of nutrients were 
commercialized.16 These will be addressed in detail (Part 
II, section 2).
Individualized PN prescription with hospital pharmacy 
compounding should be preferred in very and extremely 
preterm infants at risk of metabolic imbalances, including 
hypo- and hyperglycemia, hypo- and hypernatremia, 
and hypo- and hyperkalemia.16 
Recently, the Instituto Nacional da Farmácia e do 
Medicamento (INFARMED) authorized (not yet in 
practice) the distribution in the national market of 
commercial neonatal PN solution bags (B Braun®) 
manufactured in Spain, according to individualized 
prescription.  
The addition of a drug to the PN solution or its infusion 
by Y-connection system with PN infusion should be 
strictly evaluated and supported by studies, since 
such procedure may interfere with the stability and 
physicochemical compatibility of PN components, 
affecting the effectiveness of both the PN and the drug.17
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5. Estimation of  osmolality 
When nutrients are prescribed by PN at the 
recommended doses,18 the osmolality of neonatal PN 
solutions rapidly exceeds 900 mOsm/kg of water.19 
Osmolality is expressed in mOsm/kg of water (solvent) 
and osmolarity in mOsm/L of solution (solute plus 
solvent). As osmolality is obtained by measurement 
and osmolarity by calculation,20,21 a simple equation for 
estimating the osmolality of neonatal PN solutions was 
validated by osmometry relying on concentrations of the 
four most influential components: glucose, amino acids, 
phosphorus, and sodium. The concentrations of glucose 
and amino acids are expressed as g/L, phosphorus in 
mg/L, and sodium in mEq/L.19 Osmolarity (mOsm/ L) 
= (amino acids x 8) + (glucose x 7) + (sodium x 2) + 
(phosphorus x 0.2) - 50; it may be expressed in molar 
concentrations of nitrogen and other components. 
This equation was shown to have a good correlation 
with equations proposed by the American Society for 
Parenteral and Enteral Nutrition (ASPEN)22 and has 
been suggested by several authors.21,23-25 It can be 
incorporated into spreadsheets and computer programs. 
Since osmolarity is reported to underestimate osmolality 
at high concentrations,26 equations and algorithms 
have been subsequently proposed for more accurate 
estimates of osmolality of neonatal PN solutions,20,26 
including a commercialized program.26
6. Routes of  administration
In binary PN mixtures, the aqueous solution with 
glucose and amino acids is generally infused through 
a single line, to which the lipid emulsion is infused 
by a Y-connection system as close as possible to the 
venipuncture site or the catheter insertion.3
The option of infusing PN peripherally or centrally 
depends on several factors, including the expected 
duration of PN, the osmolality of the solution, and the 
ease of access of a central route.3,14
6.1.  Peripheral
- Indications: The expected duration of PN is less than 
two weeks, available veins are favorable for peripheral 
access, and nutritional status is good. 
- Limitations: Frequent venipuncture and insufficient 
intakes of energy and nutrients, since solutions with 
recommended nutrients content are hyperosmolar.19,27,28 
6.2. Central 
- Indications: The duration of PN is expected to be 
prolonged, osmolarity of the PN solution exceeds 900 
mOsm/L, and/or glucose concentration exceeds 12.5 g/
dL in the final solution.14,18,21 
- Limitations: The difficulties in catheter insertion or its 
contraindication in the acute phase of infection. Even 
using the central route, the osmolarity of the final solution 
should not exceed 1,700 mOsm/L14 or 15 g/dL of glucose.29 
- Type of central catheter according to the expected 
duration of PN30-33: 
1) Peripherally inserted central catheter (epicutaneous 
cava catheter), or centrally inserted venous catheter 
(e.g. in the subclavian vein, Arrow® type) - if PN < 2-3 
weeks;
2) Tunneled central venous catheter (e.g. Broviac® type) 
- if PN > 2-3 weeks; 
- Umbilical vessels: Vein (catheter tip ideally at entrance 
of the right atrium), especially in neonates < 1,000 g, for 
short-term use (< five days) and peripheral access not 
available. Artery, only when there is no alternative and 
its use is very temporary (< 48 hours). 
In multi-lumen catheters, one lumen should be 
exclusively used for PN infusion.33
7. Heparinization for central venous 
catheters patency
There is controversy about the advantage of the 
prophylactic addition of heparin to PN solutions to avoid 
the occlusion of central venous catheters. Currently, 
ESPGHAN/ESPEN/ESPR/CSPEM do not recommend its 
routine prophylactic use (LoE 3, RG 0)33 and the ASPEN 
has a similar position, but while recognizing that the 
recommendation grade is weak.14 Nevertheless, a recent 
systematic review concluded that the prophylactic 
heparinization by continuous infusion in indwelling 
long catheters is advantageous to prolong the longevity 
of long lines in preterm infants.34 As this systematic 
review was not included in the reference list of the 
updated guidelines of ESPGHAN/ESPEN/ESPR/CSPEM,33 
it is left on the physician discretion to use 10-15 IU/kg/
day of heparin added to a PN aqueous solution.34 An 
approximate daily dose that has been commonly used 
and easier to prescribe is 0.5 IU/mL,23 although this may 
exceed 15 IU/kg/day. 
As an alternative to the aforementioned routine 
prophylactic heparinization, flushing with small volumes 
of heparinized saline (5-10 IU/mL), 1-2 times per week 
may be used to maintain the patency of intermittently 
accessed central venous catheters (LoE 2, RG 0).33  
Heparin should not be added to lipid emulsions because 
it can alter its stability (LoE 3, RG GPP).13
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8. Storage and intravenous infusion 
conditions
The two main factors that determine the stability of 
PN solutions during storage are temperature and light 
exposure.14,35
A comprehensive study addressing the physicochemical 
stability of binary mixtures of neonatal PN concluded 
that they remain stable for four months at 4ºC-8ºC.36 
All PN solutions should be protected from natural and 
artificial light (including phototherapy) during storage 
and infusion in order to reduce the degradation of 
some vitamins and the formation of hydrogen and lipid 
peroxides.35,37 For this purpose, using multilayer bags 
(less oxygen-permeable), reinforced photoprotective 
bags, and opaque infusion systems or shielding the bag, 
syringe and all the infusion tubing from ambient light, 
are recommended.17 
In order to retain microparticles or precipitates, the use 
of 1.2 µ filters for the infusion of ternary mixtures and 
0.22 µ for binary mixtures is recommended.17
9. Complications
Complications most frequently associated to neonatal 
PN include28,38:
Central venous catheter-related sepsis: This should 
be suspected if the body temperature is > 38.5ºC, 
or rises > 1ºC, or there is a new-onset tachycardia, 
hyperglycemia, hemodynamic instability, and/or 
changes in the laboratory parameters. Central and 
peripheral blood cultures are recommended prior to 
the initiation of empirical antibiotic therapy. If a good 
response occurs in 48-72 hours, antibiotic therapy 
should be maintained for 10-14 days. In case of clinical 
deterioration or persistence of bacteremia, the catheter 
should be removed.
Thrombotic occlusion of central venous catheter: 
Immediate onset of thrombolytics is recommended; 
the recombinant tissue plasminogen activator (rtPA) 
is most often indicated, but urokinase can be used 
instead. Antithrombotic drugs should also be used for 
the subsequent maintenance of the catheter.
Extravasation, migration, and fracture of central venous 
catheter: The removal of the catheter or removal of the 
fractured fragment is recommended as soon as possible.
Parenteral mineral intake to prevent bone metabolic 
disease (Part II, section 1.4) and parenteral intake of 
nutrients in PN associated cholestasis will be detailed 
(Part II, section 3).
10. Clinical and laboratory monitoring 
10.1. Anthropometry35,39
- Daily: body weight; 
- Weekly: body length and head circumference. 
The appropriate curves and reference values should be 
used to monitor growth particularly in preterm infants40.
At birth, the Fenton curves41 are appropriate. For the 
first postnatal days, a body weight calculator (www.
growthcalculator.org) based on the Landau-Crangle 
curves42 became recently freely accessible online.43 For 
the long term, the Intergrowth 21st curves are more 
appropriate.44 
After the initial physiological weight loss, the weight 
gain velocity in very and extremely preterm infants 
should ideally be of 17-20 g/kg/day.45
10.2. Laboratory39,46,47
If the infant is receiving predominantly or exclusively PN:
- In the first postnatal week: Three times daily to 
daily: blood gases, glycemia (for the infant’s comfort, 
measurements from blood gases analyzers should be 
preferred), serum ionogram, serum calcium, urine 
specific gravity if possible, and glycosuria (e.g. Multistix®). 
Every three days, if under exclusive PN: complete blood 
count, blood urea or blood urea nitrogen (BUN), and 
serum creatinine. Baseline serum levels of phosphorus, 
alkaline phosphatase, and magnesium may be measured.
- After the first postnatal week: Weekly assessment 
of: the aforementioned parameters plus serum levels 
of transaminases, alkaline phosphatase, total and 
conjugated bilirubin, γ-glutamyl transpeptidase (γ-GT), 
albumin, and triglycerides. Using the micromethods 
currently available, a 1-2 mL blood sample is usually 
enough to perform these measurements. 
To avoid excessive blood spoliation in very and extremely 
preterm infants, the periodicity of analytical monitoring 
may be extended and adapted to the clinical condition.
11. Individualized prescription
11.1. Fluids (Table 1)
Comments:
- Within the first postnatal days, the major determinants 
of water balance in the very preterm infants are the 
relative oliguria and transepidermal water loss.48,49 In 
order to not exceed the recommended fluid intake, it 
is necessary to counteract the transepidermal water 
loss by providing 80%-90% of environment humidity 
and neutral temperature, preferably using a double wall 
incubator.48,50-53 As the epidermis keratinizes rapidly, 
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the supplemental humidity should be progressively 
decreased to the environment values after the fifth 
postnatal day to reduce the risk of infection.48 A 
complementary strategy to reduce the transepidermal 
water loss is to cover these preterm infants with 
plastic bags and wraps.48 Following the relative oliguric 
phase, diuresis and natriuresis are established, and it is 
expected that very and extremely preterm infants will 
lose 7%-10% of birth weight (LoE 2++, RG B).48 Infants 
with intrauterine growth restriction lose less weight 
than appropriate for gestational age infants.48,54   
- It may be necessary to increase fluid intake (around 10% of 
the baseline needs) if an open incubator or phototherapy 
are used,48,49,55 although the routine fluid intake increase 
to compensate for phototherapy is controversial.50
- In very and extremely preterm infants, excessive fluid 
intake predisposes them to persistent ductus arteriosus, 
chronic lung disease, and necrotizing enterocolitis.52
Parameters guiding the prescription:
- Urine specific gravity: Ideally it should be between 
1,005-1,010, roughly corresponding to osmolalities 
between 100-300 mOsm/kg water.56
- Serum sodium: In the first postnatal week it may 
reflect the hydration status (hyponatremia indicates 
hyperhydration and hypernatremia dehydration).57 
- Diuresis: Ideally it should be 1-3 mL/kg/h; oliguria is 
defined as < 0.5-1 mL/kg/h and polyuria as > 6-7 mL/
kg/h.48,49 
- Body weight changes: In the first postnatal days, weight 
changes reflect the hydration status. Reference values 
that consider the physiological postnatal weight loss 
should be used,40,58 such as what was recently published.42
11.2. Energy (Table 2)
Comments:
- An excessive energy intake predisposes to an 
exaggerated accumulation of fat mass, and an 
insufficient energy intake may negatively affect growth, 
neurodevelopment, and immunity.45,47
- Ideally, glucose should contribute with 45%-55% of 
total energy, lipids with 30%-40% and amino acids with 
10%-15%.18,59 Lipids should not exceed 40%-60% of non-
protein energy intake.60
- Each gram of glucose and amino acids provides 4 kcal, 
and each gram of lipids provides 9 kcal.61
11.3. Glucose (Table 2)
Comments:
- Although the maximum recommended dose of glucose 
is 12 mg/kg/min,47 its maximum oxidation capacity is 8.3 
mg/kg/min in preterm infants (12 g/kg/day).63
- Excessive glucose intake should be avoided because it 
predisposes to lipogenesis and excessive fat storage, and 
increased susceptibility to infections and retinopathy of 
prematurity (LoE 2+, RG B).46,47,63
- Conditions like stress, infection, and methylxanthines 
therapy predispose to hyperglycemia.64 In the acute 
phase of disease (e.g. sepsis), glucose intake should not 
exceed 5-7 mg/kg/min (LoE 4, RG GPP).47
- In case of hyperglycemia (> 145 mg/dL), the dose of 
glucose should be decreased. It may also be necessary 
to decrease the dose of lipids due to their hyperglycemic 
effect mediated by gluconeogenesis.64 
- The use of insulin should only be considered if 
hyperglycemia persists despite reduction of glucose 
intake to 4 mg/kg/min,18, and/or if glycemia is repeatedly 
higher than 180 mg/dL (LoE 2+, RG 0).47
Parameters guiding the prescription:
- Venous or capillary blood glucose levels: > 145 mg/
dL constitute hyperglycemia, and those < 40 mg/dL 
hypoglycemia.47,64 For the infants comfort, measurements 
from blood gas analyzers should be preferred (LoE 2+, 
RG B).47
- Search for glycosuria (reagent strips).64
11.4. Amino acids (Table 4)
Comments:
- Parenteral administration of amino acids is less 
physiological than enteral administration, since they are 
directly infused into the systemic circulation bypassing 
the hepatic and splanchnic metabolism.53,65
- To promote nitrogen retention, the intake of non-
protein energy should be at least 65 kcal/kg/day (LoE 1+, 
RG A).65 Nevertheless, if the non-protein energy intake 
is lower, the dose of amino acids should not be limited, 
since the amount that is not used for nitrogen retention 
is oxidized for energy production.45
- Two recent systematic reviews have concluded that 
high parenteral doses (> 3 g/kg/day) of amino acids 
administered early (< 24 postnatal hours) are safe and 
well tolerated, resulting in a positive nitrogen balance, 
D - day, LoE - level of evidence. 
Table 1. Daily intakes (mL/kg) of fluids during the first postnatal week (LoE 4)4,48
Postnatal day D1 D2 D3 D4 D5 ≥ D6
Term infants 40-60 50-70 60-80 60-100 100-140 140-170
Preterm >1,500 g 60-80 80-100 100-120 120-140 140-160 140-160
Preterm < 1,500 g 80-100 100-120 120 -140 140-160 160-180 140-160
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although limited evidence exists on their advantages 
on growth, neurodevelopment, and retinopathy of 
prematurity.66,67 In very and extremely preterm infants, 
high doses of amino acids and lipids during the first 
postnatal week (as currently recommended) may be 
independently associated with non-lactic metabolic 
acidosis.68 
- In preterm infants, the early onset of intravenous 
amino acids stimulates endogenous insulin secretion 
and may prevent hyperglycemia without increasing the 
risk of hypoglycemia.24,25,60
- The profile of parenteral amino acid solutions is generally 
based on the umbilical cord blood aminoacidogram (e.g. 
Primene®, Baxter) or on the plasma aminoacidogram of 
healthy breastfed newborns (e.g. Vaminolact®, Fresenius 
Kabi).53,59,69 
- In very and extremely preterm infants, more 
concentrated solutions (e.g. 10 g/dL) should be 
preferred since they provide the appropriate dose at a 
lower volume.18,46 
- Specific amino acids65,70: 
- Cysteine is a semi essential amino acid, with a 
recommended dose of 50-75 mg/kg/day. Cysteine 
may have to be added to the PN solution before its 
administration due to its low solubility (LoE 1+, RG B); 
for instance, cysteine may be required if Vaminolact® 
(Fresenius Kabi), which contains 100 mg cysteine/dL, is 
used, but not in case of Primene® (Baxter) that contains 
the sufficient amount of 189 mg cysteine/dL. 
- Tyrosine is another semi-essential amino acid; a 
minimum daily dose of 18 mg/kg is required in preterm 
infants (LoE 2++, RG B) and 94 mg/kg in term infants 
(LoE 1+, RG B).
- Glutamine instability makes its inclusion in commercial 
solutions impossible; its addition to PN solutions is not 
recommended (LoE 1++, RG A).
- Arginine may be used in preterm infants to prevent 
necrotizing enterocolitis (LoE 1, RG B).  
Parameters guiding the prescription:
- Blood urea and blood urea nitrogen (BUN): Reference 
values for BUN: 5.5-22 mg/dL. Blood urea is 2.14 times 
the BUN value (e.g. 20 mg/dL of urea equals 9.3 mg/dL 
of BUN). BUN level is a good indicator of protein intake, 
except in the early postnatal days when it is influenced 
by the hydration status and renal function.71 A low BUN 
value indicates insufficient nitrogen intake, but a value 
at the upper threshold may simply reflect efficient 
oxidation of amino acids and not their intolerance.29
- Blood gases: Metabolic acidosis (defined as base excess) 
should be checked in the first postnatal week when 
it may appear associated to currently recommended 
doses of amino acids and lipids.68
11.5. Lipids (Table 5)
Comments:
- Intravenous lipid emulsions are good sources of energy, 
essential fatty acids, and substrate for physiological fat 
accretion especially in very and extremely preterm 
infants who are born without fat stores.53,60
- To avoid a deficit in essential fatty acids, which 
occurs after 72 hours without exogenous supply, the 
minimum dose of 1 g/kg/day is needed using the 
current lipid emulsions containing soybean oil, medium 
chain triglycerides and/or fish oil.13 The minimum 
recommended dose of linoleic acid is 0.25 g/kg/day in 
preterm infants (LoE 2, RG 0) and 0.1 g/kg/d in the term 
infants (LoE 3-4, RG 0), its content varying according to 
the type of lipid emulsion used.13 
D - day; LoE - level of evidence; RG - recommendation grade.
* LoE 2+, RG 0.
† LoE 2++, RG B.
Table 2. Daily intakes (kcal/kg) of energy recommended by 
parenteral nutrition45,59
Postnatal day D1 D2-6 ≥ D7




LoE - level of evidence; RG - recommendation grade.
Table 3. Intakes (mg/kg/min or g/g/day) of glucose recommended 
by parenteral nutrition (LoE 2+, RG B)18,47,62
- Onset: term infants 2.5-5 mg/kg/min; preterm infants 4-8 mg/
kg/min
- Subsequently, increase gradually by 1-2 mg/kg/min, adjusting to 
maintain glycemia between 45-120 mg/dL
- Minimum: term infants 2.5 mg/kg/min (3.6 g/kg/day); preterm 
infants 4 mg/kg/min (5.8 g/kg/day)
- Maximum: 12 mg/kg/min (17.3 g/kg/day) in term and preterm 
infants
Table 4. Daily intakes (g/kg) of amino acids recommended by 
parenteral nutrition65
Postnatal day D1 ≥ D2 Maximum
Term infants* > 1.5 2.5-3.0 3.0
Preterm 
infants† > 1.5 2.5-3.5 3.5
D - day; LoE - level of evidence; RG - recommendation grade.
* LoE 1+, RG B. 
† LoE 1++, RG A.
Table 5. Daily intakes (g/kg) of lipids recommended by parenteral 
nutrition13
- Onset: 1-2 g/kg from the first postnatal day (LoE 1, RG A)
- Daily increase of 0.5-1 g/kg up to the maximum of 4 g/kg (LoE 4)
- 24 hours continuous infusion (LoE 2++, RG B)
LoE - level of evidence; RG - recommendation grade.
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- Ideally, the lipid emulsion should contain n-6 and n-3 fatty 
acids (fish oil), components with good antioxidant capacity 
(e.g. α-tocopherol and monounsaturated fatty acids) and, 
possibly, medium chain fatty acids (less carnitine-dependent) 
(LoE 1, RG A).28,60 A systematic review concluded that lipid 
emulsions containing fish oil are effective in reversing PN 
associated cholestasis, but not in preventing it.72 
- Serum triglyceride clearance: 20% (instead of 10%) lipid 
emulsions should be used because their phospholipid 
content is lower, resulting in more efficient triglyceride 
clearance (LoE 1, RG B).13,60 Serum triglycerides clearance 
depends on the activity of endothelial lipoprotein 
lipase, which is stimulated by heparin. However, 
there is no clinical evidence that the use of heparin 
improves the use of intravenous lipids.4 In one trial, 
an emulsion containing soybean oil, fish oil, medium 
chain triglycerides, and olive oil resulted in better serum 
triglycerides clearance than an emulsion containing only 
soybean oil and medium chain triglycerides.73 
- Corticosteroids and liposomal amphotericin B may 
transiently increase triglyceridemia.46
- Although preterm infants are deficient in carnitine 
(which facilitates the transport of fatty acids into the 
mitochondria for oxidation), its supplementation did not 
show any advantage (LoE 3-4).74
- Since intravenous lipid emulsions are isosmolar75 they 
can be infused peripherally.18,76
- Especially in preterm infants, the entire infusion system 
(syringe, tubes) for lipid emulsions must be light protected, 
particularly from phototherapy, to reduce lipid and hydrogen 
peroxide formation and cellular damage (LoE 1, RG B).13,37
- Unproven concerns with intravenous lipids that should 
not limit their use46,60: 1) It had not been proven that 
intravenous lipids predispose to chronic lung disease 
or retinopathy of prematurity; 2) In thrombocytopenia, 
other cofactors are probably responsible for the adverse 
effects attributed to lipids, such as vitamin E deficiency 
(interfering with platelet count) and the administration 
of heparin (interfering with platelet function); 3) In 
vitro and in vivo studies have not clearly demonstrated 
a negative interference of intravenous lipids with the 
immune system, in particular with monocyte activity; 
and 4) The use of intravenous lipids may predispose 
to infection by coagulase negative Staphylococcus and 
Candida, but the nutritional advantages of their use 
clearly outweigh these risks.
- In unconjugated hyperbilirubinemia (Part II, section 3.3), 
acute phase of sepsis (Part II, section 3.1), pulmonary 
hypertension (Part II, section 3.4), and severe and 
unexplained thrombocytopenia, it may be necessary to 
reduce lipids to a minimum dose capable of preventing 
essential fatty acids deficit.13,53 
Parameters guiding the prescription:
- Triglyceridemia should not exceed 265 mg/dL (LoE 4).13
- Blood gases: Metabolic acidosis (defined as base excess) 
should be checked in the first postnatal week when it 
may appear associated with currently recommended 
doses of amino acids and lipids.68
12. Conclusions
Newborn infants totally or partially unable to use the 
enteral route should be parenterally fed. Parenteral 
nutrition is especially important in very and extremely 
preterm infants because they were born deprived of the 
third trimester of gestation, a period characterized by a 
high transfer of nutrients to the fetus.
In the early postnatal hours, it is essential to provide an 
adequate amount of energy and amino acids. Lipids are 
an important source of energy and essential fatty acids. 
This update of guidelines for neonatal PN prescription 
represents a general orientation to support the clinical 
practice that should be adapted to each case.
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